IGC Pharma
About: IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Employees: 70
0
Funds holding %
of 7,434 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
14% more capital invested
Capital invested by funds: $817K [Q1] → $930K (+$114K) [Q2]
12% more funds holding
Funds holding: 25 [Q1] → 28 (+3) [Q2]
0.22% more ownership
Funds ownership: 3.6% [Q1] → 3.82% (+0.22%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4.50
1,054%
upside
Avg. target
$4.50
1,054%
upside
High target
$4.50
1,054%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo | 1,054%upside $4.50 | Buy Maintained | 26 Aug 2025 |
Financial journalist opinion
Based on 5 articles about IGC published over the past 30 days
Neutral
Accesswire
2 days ago
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer's disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma.
Neutral
Accesswire
1 week ago
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial
POTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, reported its financial results for the quarter ended June 30, 2025. Highlights in the quarter include: Accelerated progress on the Company's Phase 2 CALMA trial in Alzheimer's disease Progress in the development of MINT-AD Extension of its undrawn $12M credit facility Ram Mukunda, CEO of IGC Pharma, commented, "We began fiscal 2026 with solid strategic momentum, advancing multiple programs that we believe position IGC for meaningful value creation this fiscal year.
Negative
Zacks Investment Research
1 week ago
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
Neutral
Accesswire
2 weeks ago
IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1
Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology POTOMAC, MARYLAND / ACCESS Newswire / August 12, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced promising preclinical results for IGC-M3, a novel small molecule designed to address multiple biological drivers of Alzheimer's disease. IGC-M3 demonstrated activity in laboratory models against beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation, four key contributors to Alzheimer's pathology.
Neutral
Accesswire
3 weeks ago
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression
- New hope in Alzheimer's: IGC-M3 targets the disease on four fronts, showing promise in cellular models - POTOMAC, MD / ACCESS Newswire / August 5, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today announced encouraging preclinical data on its investigational molecule "IGC-M3". The invitro results demonstrates that IGC-M3 may offer disease-modifying potential by targeting multiple biological mechanisms central to Alzheimer's pathology, including amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation.
Neutral
Accesswire
1 month ago
IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025
- Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings - POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the presentation of three scientific posters at the 2025 Alzheimer's Association International Conference ("AAIC"), taking place July 27-31 in Toronto, Canada. The poster presentations highlight advancements in the Company's proprietary artificial intelligence ("AI") platforms designed to accelerate drug discovery and improve early detection of Alzheimer's disease, particularly in low-resource settings.
Neutral
Accesswire
1 month ago
IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D., has been awarded the Best Researcher Award at the 11th Annual World Neuroscientist Awards.
Neutral
Accesswire
1 month ago
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics - POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer's, the Company's proprietary AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear. MINT-AD leverages diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
Neutral
Accesswire
1 month ago
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation
POTOMAC, MARYLAND / ACCESS Newswire / June 30, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today unveiled the key achievements and advancements that defined Fiscal Year 2025, ended March 31, 2025. This past year has been nothing short of transformative, marked by significant clinical progress, strategic expansion, and growing recognition for our pioneering approach to Alzheimer's disease.
Neutral
Zacks Investment Research
1 month ago
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
Charts implemented using Lightweight Charts™